Editorial: New strategies for the treatment of advanced melanoma and non-melanoma skin cancerdoi:10.3389/fmed.2024.1366008Villani, AlessiaPotestio, LucaLallas, AimiliosFrontiers in Medicine
There have been major advances in the immunotherapy of cancer in recent years, including the development of T cell engagers — antibodies engineered to redirect T cells to recognize and kill cancer cells — for the treatment of haematological malignancies. However, the field still faces several chal...
MSOR12Presentation Time: 8:55 AM: Skin Brachytherapy, an Alternative Treatment for Non-Melanoma Skin Cancer: A Case Series from a Low Middle Income Country... Worldwide, non-melanoma skin cancer (NMSC) has a high incidence. In 2020, Colombia, a Latin American country, had a NMSC ...
Immunotherapy has become a mainstay in the treatment of metastatic melanoma. Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) inhibitors and programmed death-1 (PD-1) inhibitors, which have been added more recently, represent two of the main classes of immunomodulating agents. PD-1 inhibitors...
Published online December 11, 2024. doi:10.1001/jamadermatol.2024.4819 This cohort study evaluates the association between cutaneous melanoma tumor mutational burden and indoor tanning exposure, as well as other demographic, dermatologic, and tumor characteristics. Observation Successful Treatment of Mogamu...
[20]. Dai D, Gu S, Han X, et al. The transcription factor ZEB2 drives the formation of age-associated B cells. Science. 2024;383(6681):413-421. [21]. Yin H, Li L, Feng X, et al. 2D4, a humanized monoclonal antibody targ...
被引量: 0发表: 2024年 Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends breakthrough in the treatment prospect.Over the past decades,these agents have demonstrated dramatic efficacy,especially in patients with melanoma and non-... Q Sun,Z Hong,C Zhang,... - 信号...
[4]Mao L, Lian B, Li C, et al. Camrelizumab plus apatinib and temozolomide as first-line treatment in patients with advanced acral melanoma: the CAP 03 phase 2 nonrandomized clinical trial[J]. JAMA oncology, 2023, 9(8):...
Key data from Merck’s pipeline to be presented at ASCO 2024: First presentation of three-year follow-up data from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial evaluating mRNA-4157 (V940) in combination with KEYTRUDA as adjuva...
Antibody therapies for melanoma: New and emerging opportunities to activate immunity (Review) immune cell interactions have helped to identify checkpoint molecules on immune (CTLA4, PD-1) and tumour (PD-L1) cells as promising therapeutic targets. ... S Malas,M Harrasser,K Lacy,... - 《Oncolo...